Want to see FR:ALTHX full AI Analyst Report?
Theranexus SA (ALTHX) AI Stock Analysis
Theranexus SA
(Paris:ALTHX)
The overall score is very low, driven primarily by the company's weak financial performance, including zero revenue and ongoing losses. Bearish technical momentum and a negative P/E ratio further weigh on the assessment. The key mitigating factor is the improving cash flow trend, which suggests a path toward breakeven, but this is not yet sufficient to offset the significant fundamental risks.
Theranexus SA (ALTHX) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 47.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 80.94K
- Price to Earnings (P/E)
- -34.2
- Beta (1Y)
- 0.29
- Revenue Growth
- ―
- EPS Growth
- 54.40%
- Country
- France
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Theranexus SA Business Overview & Revenue Model
Company Description
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation f...
How the Company Makes Money
Theranexus is a clinical-stage biopharmaceutical company; detailed, consistently disclosed product-sales revenue information is not available here, and the company is not generally expected to generate meaningful recurring revenue from commercial dru...
Theranexus SA Financial Statement Overview
Summary
Financial health is precarious. The income statement reflects zero revenue and substantial operating losses, scoring 20. The balance sheet shows improvement with positive equity but remains fragile with elevated debt-to-equity, scoring 35. Cash flow is trending positively with a significantly reduced burn rate, scoring 40. Overall, the company is high-risk with a thin financial cushion.
Income Statement
20Very NegativeBalance Sheet
35NegativeCash Flow
40Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.26M | 0 | 2.28M | 296.33K | 414.90K | 602 |
| Gross Profit | 1.03M | -108.60K | -333.55K | -4.64M | 82.90K | -8.82M |
| EBITDA | -9.76M | -10.12M | -2.53M | -7.39M | -5.93M | -8.67M |
| Net Income | -2.03M | -3.00M | -1.77M | -6.83M | -6.57M | -8.15M |
Balance Sheet | ||||||
| Total Assets | 22.63M | 10.54M | 3.74M | 7.24M | 12.05M | 16.89M |
| Cash, Cash Equivalents and Short-Term Investments | 17.45M | 7.77M | 966.59K | 4.90M | 9.11M | 12.53M |
| Total Debt | 2.59M | 2.88M | 2.87M | 3.64M | 4.89M | 5.33M |
| Total Liabilities | 19.66M | 7.64M | 5.40M | 5.02M | 6.33M | 6.71M |
| Stockholders Equity | 2.98M | 1.99M | -1.66M | 2.22M | 5.73M | 10.18M |
Cash Flow | ||||||
| Free Cash Flow | 8.86M | -939.81K | -3.40M | -6.40M | -5.41M | -6.40M |
| Operating Cash Flow | 9.07M | -883.76K | -3.37M | -6.36M | -5.37M | -6.25M |
| Investing Cash Flow | -319.59K | -168.23K | 77.04K | -61.11K | 323.53K | -150.62K |
| Financing Cash Flow | 7.74M | 7.85M | -646.42K | 2.22M | 1.63M | 7.71M |
Theranexus SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHX, the sentiment is Neutral. The current price of 3.27 is above the 20-day moving average (MA) of 3.21, below the 50-day MA of 3.46, and below the 200-day MA of 3.42, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 77.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALTHX.
Theranexus SA Peers Comparison
Overall Rating
FR:MEDCL50Neutral
FR:ALSEN45Neutral
FR:SIGHT43Neutral- FR:ALTHX41Neutral
FR:AB39Underperform
FR:ALINS21Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:MEDCL | 50Neutral | EUR 948.13M | -28.97 | ― | ― | -23.21% | -50.69% |
| FR:ALSEN | 45Neutral | EUR 87.32M | -2.04 | -54.15% | ― | ― | 6.26% |
| FR:SIGHT | 43Neutral | EUR 18.98M | -1.06 | 52.39% | ― | -610.31% | 43.88% |
| FR:ALTHX | 41Neutral | EUR 47.79M | -34.16 | -81.82% | ― | ― | 54.40% |
| FR:AB | 39Underperform | EUR 52.22M | -6.72 | 27.28% | ― | 12.66% | 44.01% |
| FR:ALINS | 21Underperform | EUR 10.82M | -0.76 | 148.60% | ― | -24.18% | -120.44% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALTHX | Theranexus SA | 3.31 | 1.47 | 79.99% | |
| FR:SIGHT | GenSight Biologics | 0.08 | -0.05 | -38.89% | |
| FR:AB | Ab Science | 0.54 | -0.64 | -54.31% | |
| FR:ALSEN | Sensorion SAS | 8.64 | -8.86 | -50.63% | |
| FR:ALINS | Intrasense SA | 0.20 | -0.07 | -24.63% | |
| FR:MEDCL | MedinCell SA | 26.36 | -10.42 | -28.33% |
Theranexus SA Corporate Events
THX Pharma Nears Break-Even as Rare Disease Pivot Gains Traction
THX Pharma reported a near break-even performance for the first half of 2026, underpinned by €3.24 million in revenue and a sharply reduced net loss of €0.1 million compared with €1.07 million a year earlier. The improvement stems l...
THX Pharma Secures Long-Term European Patent Protection for Batten-1
THX Pharma and the Beyond Batten Disease Foundation have secured a key European patent protecting the use of miglustat, the active ingredient in Batten-1, for treating juvenile Batten disease. Jointly owned by BBDF, Baylor College of Medicine and Car...
THX Pharma Advances Batten-1 With Global Phase 3 Trial Filings for Juvenile Batten Disease
THX Pharma (Theranexus), together with Beyond Batten Disease Foundation and Biocodex, has submitted regulatory applications in the United States, United Kingdom and several European countries to launch an international phase 3 trial of Batten-1, an o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 10, 2026